Taking stock of the drug industry, from the lab to the medicine chestMarch 16, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Ruby Wallau for STAT STAT+ | Sanofi becomes the third leading insulin maker to lower list prices, cutting Lantus price by 78% The cuts in insulin list prices are being made in response to mounting pressure over the cost of the lifesaving diabetes treatment. By Ed Silverman STAT+ | Here's why there aren't many cheap, generic versions of pricey inhalers Researchers say a law designed to encourage generic drug development failed to foster competition for inhalers to treat asthma and COPD. By Ed Silverman STAT+ | U.K. trade group suspends Novo Nordisk for 'serious breaches' in promoting obesity drug Novo Nordisk sponsored courses on weight management on LinkedIn for health professionals, without making clear it was involved. By Ed Silverman Manuel Balce Ceneta/AP STAT+ | Califf criticizes insurers for doing too little on drug research The FDA chief wants insurers to help with drug research. It's a new request for an old initiative to find new ways to test drugs. By John Wilkerson Listen: SVB's long biotech shadow, pushy AI algorithms, & Icahn v. Illumina STAT's Bob Herman joins us to explain how treatment algorithms powered by AI are being used by Medicare Advantage plans to deny claims. By Damian Garde and Meg Tirrell and Adam Feuerstein More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments